Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics

Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics

Abstract Background Treatment for interstitial lung disease (ILD) patients with acute respiratory failure (ARF) is challenging, and literature to guide such treatment is scarce. The reported in-hospital mortality rates of ILD patients with ARF are high (62–66%). Cyclophosphamide is considered a seco...

Full description

Bibliographic Details
Main Authors: Johanna P. van Gemert, Inge A. H. van den Berk, Esther J. Nossent, Leo M. A. Heunks, Rene E. Jonkers, Alexander P. Vlaar, Peter I. Bonta
Format: Article
Language:English
Published: BMC 2021-07-01
Series:BMC Pulmonary Medicine
Subjects:
Interstitial lung disease
Acute respiratory failure
Cyclophosphamide
Ground-glass opacification
Online Access:https://doi.org/10.1186/s12890-021-01615-2

Internet

https://doi.org/10.1186/s12890-021-01615-2

Similar Items